The use of intravitreal bevacizumab in pediatric retinal and uveitic disease has become more widespread over the past decade. This article serves to outline the rationale underlying the use of intravitreal bevacizumab, and which disease entities it should be appropriately thought of as a primary or solo therapy, as opposed to an adjuvant one. Also presented is the relevant literature regarding each of these retinopathies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1177/1120672119827773 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Atezolizumab plus bevacizumab and chemotherapy as first-line therapy for cervical cancer: a cost-effectiveness analysis in the US.
Front Immunol
December 2024
Fujian Maternity and Child Health Hospital, College of Clinical Medicine for Obstetrics and Gynecology and Pediatrics, Fujian Medical University, Fuzhou, Fujian, China.
Objective: Medication is the predominant therapy for advanced cancers. However, the use of novel anticancer medications is a major contributor to disease-related financial hardships. Recently, numerous countries have mandated the pharmacoeconomic assessments of novel oncological agents to mitigate patient financial risks and optimize resource allocation.
View Article and Find Full Text PDFHereditary hemorrhagic telangiectasia: A pediatric-focused review.
Semin Pediatr Neurol
December 2024
Department of Pediatrics, University of Pittsburgh Medical Center, Children's Hospital of Pittsburgh, United States. Electronic address:
Clinical manifestations of hereditary hemorrhagic telangiectasia (HHT) include vascular malformations of the skin, nasal mucosa, gastrointestinal tract, lungs, liver and central nervous system. These malformations range from punctate telangiectasias to larger arteriovenous malformations within visceral organs and the central nervous system. Vascular malformations increase risk for acute and chronic bleeding, anemia, as well secondary complications related to arterial-venous shunting.
View Article and Find Full Text PDFCase report: Long remission and survival following immunotherapy in a case of pulmonary pleomorphic carcinoma.
Front Immunol
December 2024
Department of Oncology, First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
In 2020, we reported on a case involving a 68-year-old male patient with a rare instance of pulmonary pleomorphic carcinoma exhibiting high PD-L1 expression. The patient experienced significant therapeutic success with the use of pembrolizumab, achieving partial tumor remission. Following the publication of that report, the patient continued on pembrolizumab at a dose of 200 mg/dl for 27 cycles, subsequently transitioning to a combination of pembrolizumab and bevacizumab for eight cycles.
View Article and Find Full Text PDFNovel Fibroblast Growth Factor Receptor 3-Fatty Acid Synthase Gene Fusion in Recurrent Epithelioid Glioblastoma Linked to Aggressive Clinical Progression.
Curr Oncol
November 2024
Pediatric Hematology/Oncology, Hospital Infantil Universitario "Niño Jesús", Universidad Autónoma de Madrid, 28009 Madrid, Spain.
Glioblastoma (GBM) is the most common primary malignant brain tumor in adults, with a median overall survival (OS) of 15-18 months despite standard treatments. Approximately 8% of GBM cases exhibit genomic alterations in fibroblast growth factor receptors (FGFRs), particularly FGFR1 and FGFR3. Next-generation sequencing techniques have identified various FGFR3 fusions in GBM.
View Article and Find Full Text PDFOutcomes and Need for Additional Interventions after Intravitreal Bevacizumab for Retinopathy of Prematurity.
Ophthalmol Retina
December 2024
UT Southwestern Medical Center, Dallas, Texas; Children's Medical Center Dallas, Dallas, Texas. Electronic address:
Objective: This study investigated the outcomes of premature infants diagnosed with retinopathy of prematurity (ROP) that were treated with intravitreal bevacizumab (IVB), as well as the need for further treatment after injection.
Design: Retrospective case series.
Participants: Seventy-three premature infants born between 2016 and 2020 at a large county hospital and children's hospital.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!